Table 3.

Study outcomes.

	Antibiotics (n = 2100) % (n/N)	Standard care/placebo (n = 2097) % (n/N)	Odds ratio (95%CI)	p value
Primary outcome
Functional worsening on mRS	-	-	1.13 (0.98–1.31)	0.09
Type 1			1.08 (0.94–1.25)	0.27
Type 2			1.46 (1.02–2.09)	0.04
Unfavorable functional outcome a	52.0 (1057/2032)	52.2 (1060/2029)	0.85 (0.60–1.19)	0.348
Type 1	53.0 (1033/1949)	53.1 (1032/1942)	0.85 (0.60–1.19)	0.348
Type 2	28.9 (24/83)	32.2 (28/87)	0.25 (0.04–1.44)	0.120
Secondary outcomes
Death	16.7 (344/2066)	15.3 (316/2067)	1.13 (0.95–1.36)	0.165
Type 1	17.3 (339/1957)	16.0 (313/1952)	1.13 (0.94–1.35)	0.199
Type 2	4.6 (5/109)	2.6 (3/115)	1.82 (0.36–9.12)	0.468
Any infection	13.4 (276/2066)	20.3 (417/2059)	0.60 (0.51–0.71)	0.001
Pneumonia	9.2 (191/2066)	9.9 (205/2061)	0.92 (0.75–1.14)	0.450
UTI	3.6 (74/2066)	9.7 (201/2062)	0.34 (0.24–0.48)	<0.001
Other infection	1.7 (35/2066)	1.9 (39/2062)	0.90 (0.56–1.46)	0.639

All analyses are adjusted for age and stroke severity (NIHSS).

mRS: modified Rankin Scale; UTI: urinary tract infection.

^aUnfavorable functional outcome: mRS 3–6 or Barthel Index <60 or deceased.